Novo Will Slash US List Prices for Wegovy, Ozempic Next Year - Bloomberg.com
Novo Will Slash US List Prices for Wegovy, Ozempic Next Year Bloomberg.com
Semaglutide News
Novo to knock down Ozempic, Wegovy list prices next year, but self-pay channels unaffected - Fierce Pharma
Novo to knock down Ozempic, Wegovy list prices next year, but self-pay channels unaffected Fierce Pharma
Novo Nordisk slashing prices for weight-loss and diabetes drugs Ozempic, Wegovy and Rybelsus - The Hill
Novo Nordisk slashing prices for weight-loss and diabetes drugs Ozempic, Wegovy and Rybelsus The Hill
Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access - Yahoo Finance
Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access Yahoo Finance
Why Scientists Are Urging Caution About a Common Ingredient in Semaglutide and Ozempic - SciTechDaily
Why Scientists Are Urging Caution About a Common Ingredient in Semaglutide and Ozempic SciTechDaily
Semaglutide Not Linked to Depression Symptoms in People With HIV - MedPage Today
Semaglutide Not Linked to Depression Symptoms in People With HIV MedPage Today
Wegovy Pill From Novo Nordisk - Pharmacy Times
Wegovy Pill From Novo Nordisk Pharmacy Times
Your weight-loss drugs set to become cheaper - The Times of India
Your weight-loss drugs set to become cheaper The Times of India
Hims & Hers to Report Q4 Earnings Amid Guidance Concerns - TradingView
Hims & Hers to Report Q4 Earnings Amid Guidance Concerns TradingView
Cheaper obesity medications could come to Canada this summer, as Health Canada reviews generics - CBC
Cheaper obesity medications could come to Canada this summer, as Health Canada reviews generics CBC
Novo Nordisk Gains European Approval for Semaglutide 7.2 mg, Submits Application to FDA - HCPLive
Novo Nordisk Gains European Approval for Semaglutide 7.2 mg, Submits Application to FDA HCPLive
Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison - Nature
Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison Nature
FDA and Novo Nordisk Warn of GLP-1 Telehealth Compounding Take Down – What’s Next? - Spencer Fane
FDA and Novo Nordisk Warn of GLP-1 Telehealth Compounding Take Down – What’s Next? Spencer Fane
Novo Nordisk halves Wegovy's list price - FirstWord Pharma
Novo Nordisk halves Wegovy's list price FirstWord Pharma
Tennessee Poison Center seeing increase in calls related to weight loss medications - localmemphis.com
Tennessee Poison Center seeing increase in calls related to weight loss medications localmemphis.com
Novo Nordisk to lower list price, or wholesale acquisition cost, for Wegovy and Ozempic - PMLiVE
Novo Nordisk to lower list price, or wholesale acquisition cost, for Wegovy and Ozempic PMLiVE
Semaglutide may increase risk for nonarteritic anterior ischemic optic neuropathy - Medical Xpress
Semaglutide may increase risk for nonarteritic anterior ischemic optic neuropathy Medical Xpress
TN Poison Center sees increase in weight loss med calls - WBIR
TN Poison Center sees increase in weight loss med calls WBIR
Indian companies race to produce generic Ozempic as patent expires - CNN
Indian companies race to produce generic Ozempic as patent expires CNN
Oral Semaglutide and the GLP-1 Compounding Reckoning: From Regulatory Ambiguity to FDA Enforcement, DOJ Referrals, and Novo Nordisk’s Case Against Hims & Hers - Buchanan Ingersoll & Rooney PC
Oral Semaglutide and the GLP-1 Compounding Reckoning: From Regulatory Ambiguity to FDA Enforcement, DOJ Referrals, and Novo Nordisk’s Case Against Hims & Hers Buchanan Ingersoll & Rooney PC
New High-Dose Semaglutide: The Future of Weight Loss? - HCPLive
New High-Dose Semaglutide: The Future of Weight Loss? HCPLive
February 2026 Product Updates - Pharmacy Times
February 2026 Product Updates Pharmacy Times
How Novo Nordisk Lost Its Lead in the Weight-Loss Market - Bloomberg.com
How Novo Nordisk Lost Its Lead in the Weight-Loss Market Bloomberg.com
1 Year After CKD Approval, Semaglutide Transforms Diabetes, Kidney, and Heart Care - HCPLive
1 Year After CKD Approval, Semaglutide Transforms Diabetes, Kidney, and Heart Care HCPLive
Novo Nordisk confirms reduction in U.S. list prices for semaglutide drugs - TipRanks
Novo Nordisk confirms reduction in U.S. list prices for semaglutide drugs TipRanks
Novo Nordisk Announces 2027 Price Reduction of Wegovy, Ozempic, Rybelsus - HCPLive
Novo Nordisk Announces 2027 Price Reduction of Wegovy, Ozempic, Rybelsus HCPLive
Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access - Yahoo Finance Singapore
Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access Yahoo Finance Singapore
Novo to cut Ozempic and Wegovy prices amid intense competition - The Detroit News
Novo to cut Ozempic and Wegovy prices amid intense competition The Detroit News
Eris Lifesciences Partners With Natco Pharma To Launch Semaglutide In India - BW Healthcare
Eris Lifesciences Partners With Natco Pharma To Launch Semaglutide In India BW Healthcare
Higher dose of semaglutide increases weight loss, metabolic benefits: Newsroom - UT Southwestern
Higher dose of semaglutide increases weight loss, metabolic benefits: Newsroom UT Southwestern
FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain - fda.gov
FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain fda.gov
Novo Nordisk announces significant reduction in U.S. list price for Wegovy, Ozempic, and Rybelsus - PharmaLive
Novo Nordisk announces significant reduction in U.S. list price for Wegovy, Ozempic, and Rybelsus PharmaLive
Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice - Nature
Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice Nature
Eris Lifesciences Announces Strategic Partnership With Natco Pharma For Semaglutide Launch In India - TradingView
Eris Lifesciences Announces Strategic Partnership With Natco Pharma For Semaglutide Launch In India TradingView
More Options, More Support: New Compounded Semaglutide Pill from Hims & Hers - Hims & Hers Newsroom
More Options, More Support: New Compounded Semaglutide Pill from Hims & Hers Hims & Hers Newsroom
GoodRx to Match Novo Nordisk Price for Oral Semaglutide - AJMC
GoodRx to Match Novo Nordisk Price for Oral Semaglutide AJMC
Novo Nordisk Announces Significant Price Drops for Popular GLP-1 Medications - Pharmaceutical Executive
Novo Nordisk Announces Significant Price Drops for Popular GLP-1 Medications Pharmaceutical Executive
Novo's CagriSema loses phase 3 battle with Lilly's Zepbound, knocking 15% off share price - Fierce Biotech
Novo's CagriSema loses phase 3 battle with Lilly's Zepbound, knocking 15% off share price Fierce Biotech
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial - The Lancet
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial The Lancet
Novo’s CagriSema tops semaglutide in ph. 3 diabetes study - Fierce Biotech
Novo’s CagriSema tops semaglutide in ph. 3 diabetes study Fierce Biotech